Physician profile
Michael H Leary
NPI 1114232436
$5,452.87
in general payments reported to CMS, 2019-2025
11 companies · $643 in 2025
The $643 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $376 · 2021: $510 · 2022: $798 · 2023: $2,157 · 2024: $678 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,385 · Travel and Lodging: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,384.69 |
| Travel and Lodging | $1,093.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,588.42 | 2019-2025 | Dailies Total1 Multifocal, Dailies Aqua Comfort Plus, Air Optix |
| Bausch & Lomb Americas INC. | $1,061.44 | 2022-2025 | Infuse, Biotrue One Day, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $404.14 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $310.66 | 2020-2025 | Acuvue |
| Coopervision INC. | $306.81 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Biofinity Contact Lens |
| Abbvie INC. | $269.28 | 2022-2023 | |
| Allergan, INC. | $188.70 | 2021-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $124.99 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $50.44 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $23.00 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Leary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.